

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DC-0242

Inventors: Edward H. Abraham

Serial No.: 10/687,102

Filing Date: October 15, 2003

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Title: Method of Treating Bone Metastasis

I, Jane Massey Licata, Registration No. 32,257, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450

On this date: December 29, 2003

Jane Massey Licata  
Jane Massey Licata, Registration No. 32,257

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is attached hereto; or

( ) The fee of \$180.00 as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(I)(1).

(xx) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. \_\_\_\_\_, filed \_\_\_\_\_, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

**(XX)** All listed references are in the English language.

Respectfully submitted,



Jane Massey Licata  
Registration No. 32,257

Date: December 29, 2003

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Form PTO-1449 Modified		Docket No. DC-0242	Serial No. 10/687,102
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Edward H. Abraham	
U.S. Department of Commerce		Filing Date October 15, 2003	Group Not Yet Assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AA	Bolger et al., "Strontium-89 (Metastron) Versus External Beam Radiotherapy in Patients With Painful Bone Metastases Secondary to Prostatic Cancer: Preliminary Report of a Multicenter Trial", Seminars in Oncology 1993 20(3) (Supplemental 2):32-33
	AB	Elomaa et al., "Disphosphonates for Osteolytic Metastases", Lancet 1985 Vol. 1(8438):1155-1156
	AC	Fishman et al., "Adenosine and Other Low Molecular Weight Factors Released by Muscle Cells Inhibit Tumor Cell Growth <sup>1</sup> ", Cancer Research 1998 58:3181-3187
	AD	Estrela et al., "Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays", Nature Medicine 1995 1(1):84-88
	AE	Fang et al., "P <sub>2</sub> -Purinergic Receptor Agonists Inhibit the Growth of Androgen-independent Prostate Carcinoma Cells", J. Clin. Invest. 1992 89:191-196
	AF	Galmarini et al., "Nucleotide analogues and nucleobases in cancer treatment", Lancet Oncol. 2002 3:415-424
	AG	Janssens and Boeynaems, "Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells", Br. J. Pharmacol. 2001 132:536-546
	AH	Maymon et al., "Enhancing effect of ATP on intracellular adriamycin penetration in human ovarian cancer cell lines", Biochimica et Biophysica Acta 1994 1201:173-178
	AI	Mure et al., "Modulation of Membrane Permeability, Cell Proliferation and Cytotoxicity of Antitumor Agents by External ATP in Mouse Tumor Cells", Jpn J. Cancer Res. 1992 83:121-126

EXAMINER	DATE CONSIDERED
----------	-----------------




Form PTO-1460 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. DC-0242	Serial No. 10/687,102
		Applicant <b>Edward H. Abraham</b>	
		Filing Date October 15, 2003	Group Not Yet Assigned

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

AJ	Rapaport et al., "Growth Inhibition of Human Tumor Cells in Soft-Agar Cultures by Treatment with Low Levels of Adenosine 5'-Triphosphate", Cancer Research 1983 43:4402-4406
AK	Rapaport Eliezer, "Treatment of Human Tumor Cells With ADP or ATP Yields Arrest of Growth in the S Phase of the Cell Cycle", J. Cell Physiol. 1982 114(3):279-283
AL	Robinson Ralph G., M.D., "Strontium-89-Precursor Targeted Therapy for Pain Relief of Blastic Metastatic Disease", Cancer 1993 72:3433-3435
AM	Schroder and Rapaport, "Retinoic Acid Alters Subcellular Compartmentalization of ATP Pools in 3T3 Cells but Not in HeLa Cells", J. Cell Physiol. 1984 120(2):204-210
AN	van Holten-Verzantvoort et al., "Reduced Morbidity from Skeletal Metastases in Breast Cancer Patients During Long-Term Bisphosphonate (APD) Treatment", Lancet 1987 2(8566) 983-
AO	von Albertini et al., "Extracellular ATP and ADP Activate Transcription Factor NF- $\kappa$ B and Induce Endothelial Cell Apoptosis", Biochem. Biophys. Res. Commun. 1998 248(3):822-829
AP	von Albertini et al., "Adenosine Nucleotides Induce E-Selectin Expression in Porcine Endothelial Cells", Transplant Proc. 1997 29(1-2):1062

EXAMINER	DATE CONSIDERED
----------	-----------------



Sheet 03 of 03

Form PTO-1449 Modified

List of Patents and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce

Docket No.  
DC-0242

Serial No.  
10/687,102

Applicant  
Edward H. Abraham

Filing Date  
October 15, 2003

Group  
Not Yet Assigned

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	BA	4,291,024	9-22-81	Turcotte	424	180
	BB	5,049,372	9-17-91	Rapaport	424	1.1
	BC	4,880,918	11-14-89	Rapaport	536	27
	BD	5,641,500	6-24-97	Trepel et al.	424	422

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	NO

EXAMINER

DATE CONSIDERED